Abstract: Psoriasis is an immune-mediated and chronic inflammatory disease with a great impact on the quality of life. Adalimumab is the first fully human IgGl monoclonal antibody against tumor necrosis factor (TNF) alpha that has been approved abroad for the treatment of moderate-to-severe plaque-type psoriasis and psoriatic arthritis (PsA). Adalimumab functions by antagonizing the TNF alpha signaling pathway, and has a rapid onset of action, sustained high efficacy and favorable tolerance with no specific organ toxicity. Hence,adalimumab is a prospective drug. Nevertheless, additional studies are warranted to confirm the long-term safety of adalimumab.